

Lighting up sugars: fluorescent BODIPY-gluco-furanose and -septanose conjugates linked by direct B-O-C bonds

Bowen Liu,^a Nina Novikova,^{a,b} M. Cather Simpson,^{a,b} Mattie S. M. Timmer,^c Bridget L. Stocker,^c Tilo Söhnel,^a David C. Ware,^a and Penelope J. Brothers^{*ab}

^a School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

^b School of Chemical and Physical Sciences, Victoria University of Wellington, P.O. Box 600, Wellington 6140, New Zealand

^c The MacDiarmid Institute for Advanced Materials and Nanotechnology

Supporting Information

Experimental

General experimental

Syntheses

Figure S1: ^1H NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (400 MHz)

Figure S2: ^{11}B NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (128 MHz)

Figure S3: ^{13}C NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (75 MHz)

Figure S4: COSY NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3

Figure S5: HSQC NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3

Figure S6: HMBC NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3

Figure S7: NOESY NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3

Figure S8: ^1H NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (500 MHz)

Figure S9: ^{11}B NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (160 MHz)

Figure S10: ^{13}C NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (125 MHz)

Figure S11: COSY NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3

Figure S12: HSQC NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3

Figure S13: HMBC NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3

Figure S14: NOESY NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3

Figure S15: ^1H NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (500 MHz)

Figure S16: ^{11}B NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (160 MHz)

Figure S17: ^{13}C NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (125 MHz)

Figure S18: COSY NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3

Figure S19: HSQC NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3

Figure S20: HMBC NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3

Figure S21: NOESY NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3

Figure S22: HRMS of 1:1 α -glucofuranose BODIPY (**1**)

Figure S23: HRMS of 1:2 α -glucofuranose BODIPY (**2**)

Figure S24: HRMS of 1:2 α -glucoseptanose BODIPY (**3**)

Table S1. Details of collected X-ray data for compounds 1 and 3

Experimental

General experimental

$\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Aldrich) and N,N'-diisopropylethyl amine (Aldrich) were distilled prior to use. All other reagents were used as received (Aldrich, Fluka). Silica (DAVISIL® LC150A 35–70 μm) was used for flash chromatography. Brockmann Grade I basic alumina, deactivated using standard procedures to Grade V was used to purify the complexes. ^1H , ^{13}C , ^{11}B , COSY and NOESY spectra were recorded on Bruker Avance AV 300, Bruker Avance AVIII 400 or Bruker Avance AVIII-HD 500 spectrometers at 298 K. Spectra were recorded in CDCl_3 and referenced to TMS or residual solvent peaks. For ^{11}B NMR, $\text{BF}_3 \cdot \text{Et}_2\text{O}$ was used as external reference. Accurate mass calculations were referenced to polyethyleneglycol (PEG). ESI and LDI-TOF mass spectra were recorded on Bruker microTOF-QII and Waters Micromass MALDI micro MX, respectively, mass spectrometers. HPLC was performed on a Dionex Ultimate 3000 using a Phenomenex Gemini C18 semi-preparative column ($250 \times 10 \text{ mm}$, $5 \mu\text{m}$, 110\AA), eluted at a flow rate of 5 mL/min with detection at 210, 230, 254 and 280 nm.

The UV/Vis absorption measurements were obtained using a Shimadzu UV-Vis-NIR Spectrophotometer UV-3600 Plus and the software package UVProbe 2.50. The fluorescence measurements were obtained using a Shimadzu RF10-AXL Fluorescence Detector and Shimadzu LC Solution v1.25 SP2 software. The fluorescence quantum yields were calculated using 4,4-difluoro-8-(*p*-tolyl)-3a,4a-diaza-s-indacene (BODIPY) as a standard ($\Phi_f = 0.051$),¹ using the following model:

$$\Phi_x = \Phi_s (A_{\text{std}}/A_x) (F_{\text{std}}/F_x)$$

where Φ is fluorescence quantum yield, A is absorption at the excitation wavelength, F is the area under the curve of the emission signal, and where *std* represents a standard and *x* the unknown compound. All measurements were done using 440 nm excitation wavelength in spectroscopic grade anhydrous dichloromethane from Sigma-Aldrich used as received.

The meso-*p*-tolyl dipyrromethane was synthesized by a modified procedure² in which *p*-tolualdehyde was reacted with an excess of pyrrole under acidic conditions for three hours. The dipyrromethane was then converted into *F*-BODIPY (4,4-difluoro-8-*p*-tolyl-4-bora-3a,4a-diaza-s-indacene) using a modified literature procedure.³ Initial oxidation of the dipyrromethane with DDQ followed by treatment with $\text{BF}_3 \cdot \text{OEt}_2$ in the presence of DIPEA afforded *F*-BODIPY as a red powder after purification.

- Cui, A.; Peng, X.; Fan, J.; Chen, X.; Wu, Y.; Guo, B. *J. Photochem. Photobiol. A* **2007**, *186*, 85–92.
- Rohand, T.; Dolusic, E.; Ngo, T.; Maes, W.; Dehaen, W. *Arkivoc* **2007**, 307–324.
- Groves, B. R.; Crawford, S. M.; Lundrigan, T.; Matta, C. F.; Sowlati-Hashjin, S.; Thompson, A. *Chem. Commun.* **2012**, *49*, 816–818.

Syntheses

Cl-BODIPY (4,4-dichloro-8-*p*-tolyl-4-bora-3a,4a-diaza-*s*-indacene)

F-BODIPY (0.050 g, 0.177 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL) under N₂ atmosphere. BCl₃ (1M in CH₂Cl₂, 0.25 mL, 0.250 mmol) was added dropwise, and the reaction mixture rapidly became darker red and significantly more fluorescent under long wave UV light (365 nm). The mixture was stirred for 15 minutes, and then the solvent was removed under reduced pressure over a period of 10 minutes to result in a shiny pink solid (quantitative yield).

¹H NMR (400 MHz, CDCl₃): δ: 2.48 (s, 3H), 6.60 (m, *J* = 4.5 Hz, 2.0 Hz, 2H), 7.00 (m, *J* = 4.2 Hz, 1.0 Hz, 2H), 7.35 (m, *J* = 8.0 Hz, 2H), 7.49 (m, *J* = 8.0 Hz, 2H), 8.14 (br s, 2H).

¹³C NMR (100 MHz, CDCl₃): δ: 21.64, 119.41, 129.49, 130.56, 130.71, 132.23, 133.61, 142.05, 146.16, 147.95.


¹¹B NMR (128 MHz, CDCl₃): δ: 2.30 (s).

Glucose BODIPY esters (1-3)

Cl-BODIPY (0.104 g, 0.330 mmol) and anhydrous D-glucose (0.059 g, 0.330 mmol) were dissolved in anhydrous acetonitrile (5 mL) under N₂ atmosphere. The reaction mixture was stirred for 10 minutes and then quenched with saturated NaHCO₃ solution (7 mL). Brine (2 mL) was added to induce phase separation, and the red organic layer was separated and dried with anhydrous Na₂SO₄. The mixture was filtered and the solvent was removed under reduced pressure to result in a red oily solid. The crude product was dissolved in minimum CH₂Cl₂ and purified by column chromatography using Brockmann Grade V basic alumina. CH₂Cl₂:acetonitrile (50:1) was used to elute all the non-polar orange components, which consists of the decomplexed dipyrin species, 1:2 α-glucofuranose BODIPY (**2**), and 1:2 α-glucoseptanose BODIPY (**3**). Then CH₂Cl₂:acetonitrile (50:5) was used to elute the next orange component, which consists of dihydroxy-BODIPY produced from unreacted *Cl*-BODIPY. Finally, acetonitrile:water (50:3) was used to elute the remaining orange component, which consists of 1:1 α-glucofuranose BODIPY (**1**). This was dried under reduced pressure to result in a red solid (yield 24.2%).

The first non-polar orange component that contained 1:2 α-glucofuranose BODIPY (**2**), and 1:2 α-glucoseptanose BODIPY (**3**) was dried under reduced pressure (combined yield 9.8%). It was then dissolved in minimum CH₂Cl₂ and further purified by column chromatography using silica gel. CH₂Cl₂:acetonitrile (5:1) was used to elute the first orange component, which consists of the 1:2 α-glucofuranose BODIPY (**2**). This was dried under reduced pressure to result in a red solid. Then CH₂Cl₂:acetonitrile (5:3) was used to elute the second orange component, which consists of 1:2 α-glucoseptanose BODIPY (**3**). This was dried under reduced pressure to result in a bright orange solid.

1:1 α -glucofuranose BODIPY (1)




^1H NMR (400 MHz, CDCl_3) δ = 7.88 (t, J = 1.3 Hz, 1H, H-3 BODIPY), 7.68 (t, J = 1.3 Hz, 1H, H-3 BODIPY), 7.44 (d, $J_{o,m}$ = 8.1 Hz, 2H, H-*o*), 7.30 (d, $J_{o,m}$ = 8.1 Hz, 2H, H-*m*), 6.91 (dd, J = 3.0, 1.2 Hz, 1H, H-1 BODIPY), 6.90 (dd, J = 3.0, 1.2 Hz, 1H, H-1 BODIPY), 6.50 (dd, J = 4.2, 1.9, 1H, H-2 BODIPY), 6.47 (dd, J = 4.3, 1.9, 1H, H-2 BODIPY), 6.18 (d, $J_{1,2}$ = 2.7 Hz, 1H, H-1), 4.61 (d, $J_{1,2}$ = 3.5 Hz, 1H, H-2), 4.42 (d, $J_{3,4}$ = 2.8 Hz, 1H, H-3), 4.39 (dd, $J_{3,4}$ = 3.0 Hz, $J_{4,5}$ = 6.6 Hz, 1H, H-4), 4.15 (dt, $J_{5,6a}$ = 3.6 Hz, $J_{4,5}$ = $J_{5,6b}$ = 5.9 Hz, 1H, H-5), 3.93 (dd, $J_{5,6a}$ = 3.3 Hz, $J_{6a,6b}$ = 11.4 Hz, 1H, H-6a), 3.83 (dd, $J_{5,6b}$ = 5.7 Hz, $J_{6a,6b}$ = 11.4 Hz, 1H), 3.61 (s, 1H, OH), 3.45 (s, 1H, OH), 2.77 (s, 1H, OH), 2.45 (s, 3H, CH_3 -Ph).


^{13}C NMR (75 MHz, CDCl_3) δ 147.3 (C-*i* Ph), 145.2, 144.1 (2 x C-3 BODIPY), 141.0 (C-*p* Ph), 135.5, 135.1 (2 x C-7a BODIPY), 132.1 (C-2 BODIPY), 131.3 (C-8 BODIPY), 131.2 (C-2 BODIPY), 130.7, 129.1 (2 x C-*m* Ph), 118.8, 118.4 (2 x C-*o* Ph), 105.3 (C-1), 85.0 (C-2), 80.3 (C-4), 76.2 (C-3), 70.3 (C-5), 64.5 (C-6), 21.5 (CH_3 -Ph).

^{11}B NMR (128 MHz, CDCl_3): δ : 5.54 (s).

NOEs:



HMBCs:




HMBC between H-4/C-1 and H-1/C-4 proves the furanose ring.

$J_{1,2}$ = 2.7 Hz, $J_{2,3}$ = 0 Hz, $J_{3,4}$ = 2.8 Hz, $J_{4,5}$ = 6.6 Hz, $J_{5,6a}$ = 3.6 Hz, $J_{5,6b}$ = 5.9 Hz, $J_{6a,6b}$ = 11.4 Hz fits α -glucofuranoside.

ESI-MS: $[(\text{M} + \text{Na})^+]$: found 445.1548, calculated 445.1547 for $\text{C}_{22}\text{H}_{23}\text{BN}_2\text{O}_6\text{Na}$; $[(\text{M} + \text{K})^+]$: found 461.1288, calculated 461.1286 for $\text{C}_{22}\text{H}_{23}\text{BN}_2\text{O}_6\text{K}$.

1:2 α -glucofuranose BODIPY (2)




^1H NMR (500 MHz, CDCl_3) δ 8.07 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 8.03 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.80 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.66 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.47 (d, $J_{o,m} = 8.3$ Hz, 2H, H-*o*), 7.45 (d, $J_{o,m} = 8.3$ Hz, 2H, H-*o*), 7.311 (d, $J_{o,m} = 7.7$ Hz, 2H, H-*m*), 7.310 (d, $J_{o,m} = 7.7$ Hz, 2H, H-*m*), 6.94 (dd, $J = 4.3, 1.2$ Hz, 1H, H-1 BODIPY), 6.923 (dd, $J = 4.1, 1.4$ Hz, 1H, H-1 BODIPY), 6.918 (dd, $J = 4.0, 1.4$ Hz, 1H, H-1 BODIPY), 6.89 (dd, $J = 4.2, 1.2$ Hz, 1H, H-1 BODIPY), 6.55 (dd, $J = 4.2, 1.9$ Hz, 1H, H-2 BODIPY), 6.52 (dd, $J = 4.3, 1.8$ Hz, 1H, H-2 BODIPY), 6.47 (dd, $J = 4.3, 2.0$ Hz, 1H, H-2 BODIPY), 6.45 (dd, $J = 4.2, 2.0$ Hz, 1H, H-2 BODIPY), 6.31 (d, $J_{1,2} = 2.7$ Hz, 1H, H-1), 4.77 (dd, $J_{3,4} = 4.1, J_{4,5} = 5.7$ Hz, 1H, H-4), 4.74 (d, $J_{1,2} = 3.3$ Hz, 1H, H-2), 4.54 (d, $J_{3,4} = 4.0$ Hz, 1H, H-3), 4.11 (ddd, $J_{4,5} = 5.6, J = 3.6, J = 5.6$ Hz, 1H, H-5), 3.96 (bd, $J_{6a,6b} = 10.8$ Hz, 1H, H-6a), 3.89 – 3.79 (bm, 1H, H-6b), 2.47 (s, 6H, 2 x CH_3Ph), 2.29 (s, 1H, 6-OH).


^{13}C NMR (126 MHz, CDCl_3) δ 147.4, 147.3 (2 x C-*i* Ph), 145.5, 144.9, 143.8, 143.7 (4 x C-3 BODIPY), 141.2, 141.0 (2 x C-*p* Ph), 135.7, 135.4, 135.3, 135.2 (4 x C-7a BODIPY), 132.0 (C-2 BODIPY), 131.6, 131.5 (2 x C-8 BODIPY), 131.4, 131.2, 131.1 (3 x C-2 BODIPY), 130.8, 130.7 (4 x C-*o* Ph), 129.22, 129.16 (4 x C-*m* Ph), 118.6, 118.2, 117.8 (4 x C-1 BODIPY), 106.2 (C-1), 85.9 (C-2), 80.1 (C-4), 76.5 (C-3), 72.5 (C-5), 65.9 (C-6), 21.6 (2 x $\text{CH}_3\text{-Ph}$).

^{11}B NMR (160 MHz, CDCl_3) δ 5.67, 1.25.

COSY:



HMBCs:




COSY between 6-OH and H-6a/b shows 6-OH not involved in boron complexation.

HMBC between both H-1/C-4 and H-4/C-1 proves the furanose configuration.

$J_{1,2} = 2.7$ Hz, $J_{2,3} = 0$ Hz, $J_{3,4} = 4.1$ Hz, $J_{4,5} = 5.7$ Hz, $J_{5,6a/6b} = 3.6/5.6$, $J_{6a,6b} = 10.8$ Hz fits with α -glucofuranoside.

ESI-MS: [(M + H)⁺]: found 665.2713, calculated 665.2743 for C₃₈H₃₅B₂N₄O₆; [(M + Na)⁺]: found 687.2579, calculated 687.2562 for C₃₈H₃₄B₂N₄O₆Na.

1:2 α -glucoseptanose BODIPY (3)




¹H NMR (500 MHz, CDCl₃) δ 8.32 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 8.08 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.87 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.73 (t, $J = 1.3$ Hz, 1H, H-3 BODIPY), 7.422 (d, $J_{o,m} = 8.0$ Hz, 2H, H-*o*), 7.417 (d, $J_{o,m} = 8.0$ Hz, 2H, H-*o*), 7.29 (d, $J_{o,m} = 7.7$ Hz, 2H, H-*m*), 7.28 (d, $J_{o,m} = 7.7$ Hz, 2H, H-*m*), 6.90 – 6.87 (m, 3H, 3 x H-1 BODIPY), 6.83 (dd, $J = 4.2, 1.1$ Hz, 1H, H-1 BODIPY), 6.51 (dd, $J = 4.3, 1.9$, 1H, H-2 BODIPY), 6.49 (dd, $J = 4.3, 1.9$, 1H, H-2 BODIPY), 6.48 (dd, $J = 4.3, 1.9$, 1H, H-2 BODIPY), 6.43 (dd, $J = 4.2, 1.9$ Hz, 1H, H-2 BODIPY), 5.38 (d, $J = 3.2$ Hz, 1H, H-1), 4.81 (dd, $J_{2,3} = 7.5$ Hz, $J_{3,4} = 9.3$, 1H, H-3), 4.48 (dd, $J_{1,2} = 4.0$ Hz, $J_{2,3} = 7.4$, 1H, H-2), 4.42 (dd, $J_{5,6a} = 0.4$ Hz, $J_{6a,6b} = 13.7$ Hz, 1H, H-6a), 4.20 – 4.17 (m, 1H, H-5), 4.17 (dd, $J_{4,5} = 2.5$ Hz, $J_{3,4} = 9.3$, 1H, H-4), 3.78 (dd, $J_{5,6b} = 1.6$ Hz, $J_{6a,6b} = 14.1$, 1H, H-6b), 2.67 (s, 1H, 5-OH), 2.45 (s, 3H, CH₃-Ph), 2.45 (s, 3H, CH₃-Ph).


¹³C NMR (126 MHz, CDCl₃) δ 147.6 (C-3 BODIPY), 147.2, 146.8 (2 x C-*i* Ph), 145.3, 144.2, 143.6 (3 x C-3 BODIPY), 141.0, 140.9 (2 x C-*p* Ph), 135.7, 135.6, 135.4, 135.1 (4 x C-7a BODIPY), 131.8 (C-2 BODIPY), 131.7, 131.6 (2 x C-8 BODIPY), 131.4, 131.1 (2 x C-2 BODIPY), 130.70, 130.67 (4 x C-*o* Ph), 130.4 (C-2 BODIPY), 129.2, 129.1 (4 x C-*m* Ph), 118.9, 118.4, 117.9, 117.4 (4 x C-1 BODIPY), 106.6 (C-1), 83.4 (C-2), 78.4 (C-4), 77.4 (C-3), 71.0 (C-5), 70.8 (C-6), 21.6 (2 x CH₃-Ph).

¹¹B NMR (160 MHz, CDCl₃) δ 5.72, 4.80.

COSY:



HMBCs:



COSY between 5-OH and H-5 shows 5-OH not involved in boron complexation.

HMBC between H-6a/6b and C-1 proves oxepane ring.

$J_{1,2} = 3.2$ Hz, $J_{2,3} = 7.5$ Hz, $J_{3,4} = 9.3$ Hz, $J_{4,5} = 2.5$ Hz, $J_{5,6a} = 0.4$ Hz, $J_{5,6b} = 1.6$ Hz, $J_{6a,6b} = 14.0$ Hz.

Matches oxepane in X-ray, notably pseudo trans-diaxial H-3/H-4 with $J_{3,4} = 9.3$ Hz, and small couplings for 4,5,6 (all $J < 3$ Hz) which have near 90° dihedral angles.

ESI-MS: $[(M + H)^+]$: found 665.2710, calculated 665.2743 for $C_{38}H_{35}B_2N_4O_6$; $[(M + Na)^+]$: found 687.2579, calculated 687.2562 for $C_{38}H_{34}B_2N_4O_6Na$.

HPLC purification

Compound 1 (1:1 glucofuranose BODIPY): 10 mg of material, which was previously purified by a conventional column as described in the experimental method, was dissolved in 3 mL AR MeCN. The solution was diluted with 12 mL of milliQ H₂O and then loaded onto the HPLC column that was pre-eluted with 20:80 MeCN:H₂O. A constant gradient of 26:74 MeCN:H₂O was used. The main peak was collected and then lyophilized overnight.

Compound 2 (1:2 glucofuranose BODIPY): 1.3 mg of material, which was previously purified by a conventional column, was dissolved in 3 mL AR MeCN. The solution was diluted with 7 mL milliQ H₂O and then loaded onto the HPLC column that was pre-eluted with 30:70 MeCN:H₂O. A 30:70 MeCN:H₂O to 90:10 MeCN:H₂O gradient was set, with a 1% increase in MeCN per minute. The main peak was collected and then lyophilized overnight.

Compound 3 (1:2 glucoseptanose BODIPY): 1 mg of material, which was previously purified by a conventional column, was dissolved in 4 mL AR MeCN. The solution was diluted with 6 mL milliQ H₂O and then loaded onto the HPLC column that was pre-eluted with 40:60 MeCN:H₂O. A 30:70 MeCN:H₂O to 90:10 MeCN:H₂O gradient was set, with a 1% increase in MeCN per minute. The main peak was collected and then lyophilized overnight.

Figure S1: ^1H NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (400 MHz)




Figure S2: ^{11}B NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (128 MHz)




Figure S3: ^{13}C NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3 (75 MHz)




Figure S4: COSY NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3




Figure S5: HSQC NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3




Figure S6: HMBC NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl₃




Figure S7: NOESY NMR of 1:1 α -glucofuranose BODIPY (**1**) in CDCl_3




Figure S8: ^1H NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (500 MHz)




Figure S9: ^{11}B NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (160 MHz)




Figure S10: ^{13}C NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3 (125 MHz)




Figure S11: COSY NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3




Figure S12: HSQC NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3




Figure S13: HMBC NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl_3




Figure S14: NOESY NMR of 1:2 α -glucofuranose BODIPY (**2**) in CDCl₃




Figure S15: ^1H NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (500 MHz)




Figure S16: ^{11}B NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (160 MHz)




Figure S17: ^{13}C NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3 (125 MHz)




Figure S18: COSY NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3




Figure S19: HSQC NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3




Figure S20: HMBC NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl₃




Figure S21: NOESY NMR of 1:2 α -glucoseptanose BODIPY (**3**) in CDCl_3







Figure S22: HRMS of 1:1 α -glucofuranose BODIPY (1)

Auckland Uni Mass Spectrum SmartFormula Report


Analysis Info		Acquisition Date	13/03/2014 4:31:05 p.m.	
Analysis Name	D:\Data\Akld University\2014\Nick 03\14-03-13\Bowen000001.d			
Method	130822 - Low.m	Operator	Nick	
Sample Name	BLin A168 S4	Instrument / Ser#	micrOTOF-Q	10191
Comment	Sample dissolved in 1mL DCM Sample diluted in 1mL MeCN CCE = 8			

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Collision Cell RF	150.0 Vpp	Set Divert Valve	Source



Meas. m/z	#	Formula	Score	m/z	err [mDa]	err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
461.1288	1	C 22 H 23 B K N 2 O 6	100.00	461.1285	-0.3	-0.7	2.6	12.5	even	ok

Figure S23: HRMS of 1:2 α -glucofuranose BODIPY (2)






Figure S24: HRMS of 1:2 α -glucoseptanose BODIPY (3)




Table S1. Details of collected X-ray data for compounds **1** and **3**

	1	3
Formula	C ₄₄ H ₄₆ B ₂ N ₄ O ₁₇	C ₃₈ H ₃₄ B ₂ N ₄ O ₆
Molecular weight (g mol ⁻¹)	924.47	664.31
Temperature (K)	100(2)	100(1)
Wavelength (Å)	0.71073	1.54184
Crystal system	Monoclinic	Orthorhombic
Space group	C2	P2 ₁ 2 ₁ 2 ₁
a (Å)	37.5988(15)	11.3239(5)
b (Å)	14.8713(6)	12.8880(7)
c (Å)	8.2281(3)	25.7528(11)
β (°)	93.381(3)	90
Volume (Å ³)	4592.7(3)	3758.4(3)
Z	4	4
Calculated density (g cm ⁻³)	1.337	1.174
Absorption coefficient (mm ⁻¹)	0.103	0.643
F(000)	1936	1392
Crystal size (mm × mm × mm)	0.25 × 0.15 × 0.10	0.018 x 0.023 x 0.337
2θ (min, max) (°)	1.085, 19.70	3.835, 66.59
Limiting indices	-35 ≤ h ≤ 35, -14 ≤ k ≤ 14, -7 ≤ l ≤ 7	-13 ≤ h ≤ 10, -14 ≤ k ≤ 15, -21 ≤ l ≤ 31
Reflections collected / unique	23480 / 4060 [R(int) = 0.0461]	9143 / 5540 [R(int) = 0.0412]
Completeness to theta max	99.6 %	99.3 %
Data / restraints / parameters	4060 / 267 / 596	5540/0/454
Goodness-of-fit on F ² a)	1.081	0.998
Final R indices [I>2σ(I)] b)	R ₁ = 0.0871, wR ₂ = 0.2318	R ₁ = 0.0482, wR ₂ = 0.1290
R indices (all data)	R ₁ = 0.0920, wR ₂ = 0.2389	R ₁ = 0.0534, wR ₂ = 0.1326
Largest diff. peak and hole (eÅ ⁻³)	0.707 and -0.440	0.249 and -0.265

a) GOF = $\{\sum[w(F_o^2 - F_c^2)^2]/(n-p)\}^{1/2}$, where n is the number of reflections and p is the total number of parameters refined. b) $R_1 = \sum \|F_o\| - |F_c|/\sum|F_o| \cdot wR_2 = \{\sum[w(F_o^2 - F_c^2)^2]/\sum[w(F_o^2)^2]\}^{1/2}$.